Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole

This study has been completed.

Sponsor:

Collaborator:

Tel-Aviv Sourasky Medical Center

Information provided by (Responsible Party):

David B. Geffen, Soroka University Medical Center

ClinicalTrials.gov Identifier:

NCT00376740

First received: September 14, 2006

Last updated: August 22, 2011

Last verified: August 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	November 2010 (Final data collection date for primary outcome measure)

No publications provided by Soroka University Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Safra T, Bernstein-Molho R, Greenberg J, Pelles-Avraham S, Stephansky I, Sarid D, Inbar MJ, Stemmer SM, Geffen DB. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. Oncology. 2011;81(5-6):298-305. Epub 2011 Dec 8.

To Top